100 related articles for article (PubMed ID: 9495837)
1. Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.
Ghelardini C; Galeotti N; Gualtieri F; Marchese V; Bellucci C; Bartolini A
J Pharmacol Exp Ther; 1998 Mar; 284(3):806-16. PubMed ID: 9495837
[TBL] [Abstract][Full Text] [Related]
2. Antinociceptive profile of 3-alpha-tropanyl 2-(4-Cl-phenoxy)butyrate (SM-21) [corrected]: a novel analgesic with a presynaptic cholinergic mechanism of action.
Ghelardini C; Galeotti N; Gualtieri F; Bellucci C; Manetti D; Giotti A; Malmberg-Aiello P; Galli A; Bartolini A
J Pharmacol Exp Ther; 1997 Jul; 282(1):430-9. PubMed ID: 9223584
[TBL] [Abstract][Full Text] [Related]
3. The central cholinergic system has a role in the antinociception induced in rodents and guinea pigs by the antimigraine drug sumatriptan.
Ghelardini C; Galeotti N; Figini M; Imperato A; Nicolodi M; Sicuteri F; Gessa GL; Bartolini A
J Pharmacol Exp Ther; 1996 Nov; 279(2):884-90. PubMed ID: 8930196
[TBL] [Abstract][Full Text] [Related]
4. Antinociception induced by SM 32 depends on a central cholinergic mechanism.
Ghelardini C; Galeotti N; Gualtieri F; Novella Romanelli M; Bartolini A
Pharmacol Res; 1997 Feb; 35(2):141-7. PubMed ID: 9175584
[TBL] [Abstract][Full Text] [Related]
5. Investigation into atropine-induced antinociception.
Ghelardini C; Malmberg-Aiello P; Giotti A; Malcangio M; Bartolini A
Br J Pharmacol; 1990 Sep; 101(1):49-54. PubMed ID: 2282466
[TBL] [Abstract][Full Text] [Related]
6. M1 receptor agonist activity is not a requirement for muscarinic antinociception.
Sheardown MJ; Shannon HE; Swedberg MD; Suzdak PD; Bymaster FP; Olesen PH; Mitch CH; Ward JS; Sauerberg P
J Pharmacol Exp Ther; 1997 May; 281(2):868-75. PubMed ID: 9152396
[TBL] [Abstract][Full Text] [Related]
7. Binding profiles of a series of 2-arylpropionic acid esters on cloned human muscarinic receptor subtypes (m1-m5) and their relationship to nootropic activity.
Ghelardini C; Mizuma I; Gualtieri F; Bartolini A; Galeotti N; Romanelli MN; Teodori E
Arzneimittelforschung; 1999 Jun; 49(6):483-8. PubMed ID: 10417862
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive effects of the novel spirocyclopiperazinium salt compound LXM-10 in mice.
Yue CQ; Ye J; Li CL; Li RT; Sun Q
Pharmacol Biochem Behav; 2007 Apr; 86(4):643-50. PubMed ID: 17379285
[TBL] [Abstract][Full Text] [Related]
9. Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.
Ghelardini C; Galeotti N; Bartolini A; Furukawa S; Nitta A; Manetti D; Gualtieri F
Jpn J Pharmacol; 1998 Nov; 78(3):245-51. PubMed ID: 9869257
[TBL] [Abstract][Full Text] [Related]
10. Prochlorperazine induces central antinociception mediated by the muscarinic system.
Ghelardini C; Galeotti N; Uslenghi C; Grazioli I; Bartolini A
Pharmacol Res; 2004 Sep; 50(3):351-8. PubMed ID: 15225680
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective increase in cholinergic transmission by R-(+)-hyoscyamine.
Ghelardini C; Gualtieri F; Novella Romanelli M; Angeli P; Pepeu G; Grazia Giovannini M; Casamenti F; Malmberg-Aiello P; Giotti A; Bartolini A
Neuropharmacology; 1997 Mar; 36(3):281-94. PubMed ID: 9175606
[TBL] [Abstract][Full Text] [Related]
12. Role of histamine in rodent antinociception.
Malmberg-Aiello P; Lamberti C; Ghelardini C; Giotti A; Bartolini A
Br J Pharmacol; 1994 Apr; 111(4):1269-79. PubMed ID: 8032614
[TBL] [Abstract][Full Text] [Related]
13. Antinociception after nicotine administration into the mesopontine tegmentum of rats: evidence for muscarinic actions.
Iwamoto ET
J Pharmacol Exp Ther; 1989 Nov; 251(2):412-21. PubMed ID: 2810106
[TBL] [Abstract][Full Text] [Related]
14. The influence of central administration of dopaminergic and cholinergic agents on morphine-induced amnesia in morphine-sensitized mice.
Zarrindast MR; Farahmandfar M; Rostami P; Rezayof A
J Psychopharmacol; 2006 Jan; 20(1):59-66. PubMed ID: 16174677
[TBL] [Abstract][Full Text] [Related]
15. Role of muscarinic receptor subtypes in central antinociception.
Bartolini A; Ghelardini C; Fantetti L; Malcangio M; Malmberg-Aiello P; Giotti A
Br J Pharmacol; 1992 Jan; 105(1):77-82. PubMed ID: 1375858
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of the ameliorating effect on learning and memory impairment and antinociceptive effect of KT-95 in mice.
Hiramatsu M; Mizuno N; Kanematsu K
Behav Brain Res; 2006 Feb; 167(2):219-25. PubMed ID: 16223533
[TBL] [Abstract][Full Text] [Related]
17. In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.
Shannon HE; Womer DE; Bymaster FP; Calligaro DO; DeLapp NC; Mitch CH; Ward JS; Whitesitt CA; Swedberg MD; Sheardown MJ; Fink-Jensen A; Olesen PH; Rimvall K; Sauerberg P
Life Sci; 1997; 60(13-14):969-76. PubMed ID: 9121363
[TBL] [Abstract][Full Text] [Related]
18. Antinociception induced by systemic administration of local anaesthetics depends on a central cholinergic mechanism.
Bartolini A; Galli A; Ghelardini C; Giotti A; Malcangio M; Malmberg-Aiello P; Zucchi PL
Br J Pharmacol; 1987 Dec; 92(4):711-21. PubMed ID: 3427277
[TBL] [Abstract][Full Text] [Related]
19. Possible involvement of supraspinal opioid and GABA receptors in CDP-choline-induced antinociception in acute pain models in rats.
Hamurtekin E; Bagdas D; Gurun MS
Neurosci Lett; 2007 Jun; 420(2):116-21. PubMed ID: 17531379
[TBL] [Abstract][Full Text] [Related]
20. ABT-702 (4-amino-5-(3-bromophenyl)-7-(6-morpholinopyridin-3-yl)pyrido[2, 3-d]pyrimidine), a novel orally effective adenosine kinase inhibitor with analgesic and anti-inflammatory properties: I. In vitro characterization and acute antinociceptive effects in the mouse.
Jarvis MF; Yu H; Kohlhaas K; Alexander K; Lee CH; Jiang M; Bhagwat SS; Williams M; Kowaluk EA
J Pharmacol Exp Ther; 2000 Dec; 295(3):1156-64. PubMed ID: 11082453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
